Regeneron Pharmaceuticals (REGN) Shares are Down -2.04%

Regeneron Pharmaceuticals (REGN) has risen sharply, recording gains of 3.44% in the past 4 weeks. However, the stock has corrected -2.04% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 0.13% and the 50-Day Moving Average is 1.66%.The 200 Day SMA reached 1.44%


Regeneron Pharmaceuticals (NASDAQ:REGN): The stock opened in the green at $396.44 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $404.98 and a low of $390.56 for the day. The stock did not find buyers even at the lows and closed at $402.02 recording a loss of -1.07%. 1,114,288 shares exchanged hands during the trading day. The stock had closed at $402.02 in the previous days trading.

Regeneron Pharmaceuticals (REGN) stock is expected to deviate a maximum of $83.66 from the average target price of $475.19 for the short term period. 16 Street Experts have initiated coverage on the stock with the most promising target being $668 and the most muted being $325.

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *